3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Differentiated Thyroid Cancer
2
Adenoma, Islet Cell
2
Tuberous Sclerosis
1
Thyroid Cancer, Papillary
1
Pituitary Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Insulinoma
1
Hyperinsulinism
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Congenital Hyperinsulinism
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Advanced Extrapulmonary Neuroendocrine Cancer
1
Adenocarcinoma, Follicular
1
Acromegaly
1
Interventions
pasireotide
7
Cabergoline
7
Surgical Procedures, Operative
4
Temozolomide
3
Propofol
3
Hydrocortisone
3
Dexmedetomidine
3
lanreotide
2
Sevoflurane
2
Saline Solution
2
Rosiglitazone
2
Radiotherapy
2
Radiosurgery
2
Proton Therapy
2
Octreotide
2
Human Growth Hormone
2
Dexamethasone
2
Desflurane
2
Aminolevulinic Acid
2
pegvisomant
1
parecoxib
1
lutetium Lu 177 dotatate
1
loxoprofen
1
farletuzumab
1
entinostat
1
corticorelin ovine
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Yoga
1
Visual Field Tests
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pituitary Neoplasms
×
Injections
×
Endocrine
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled